Late presentation of alveolar capillary dysplasia with misalignment of pulmonary veins presenting as refractory pulmonary hypertension in infancy Authors: Tamer Abusido, Saleh Alshaibi, Abdullah Aldraihem, Abdulmajeed Alfadhel Published: 2026 ABSTRACT AbstractBackgroundAlveolar capillary dysplasia with misalignment of the pulmonary veins (ACD-MPV) is a rare congenital lung disorder characterized by abnormal pulmonary vascular and alveolar–capillary development, resulting in severe pulmonary hypertension (PH) that is typically refractory to therapy. Most affected infants present within the first days of life; however, delayed presentations can occur and are frequently misdiagnosed, leading to late recognition and rapid clinical deterioration.Case presentationWe report a 7-month-old girl who presented with progressive respiratory distress and severe pulmonary hypertension without an immediately identifiable cause. Initial evaluation including cardiac imaging and laboratory investigations did not reveal a clear etiology. Despite supportive management and pulmonary vasodilator therapy, the patient demonstrated persistent pulmonary hypertension with clinical deterioration. Due to the unexplained and refractory nature of the disease, lung biopsy was performed and confirmed the diagnosis of alveolar capillary dysplasia with misalignment of pulmonary veins.ConclusionThis case highlights the diagnostic challenges associated with atypical presentations of ACD-MPV beyond the neonatal period. Clinicians should consider this rare condition in infants with severe pulmonary hypertension that is disproportionate to initial findings and poorly responsive to therapy. Early recognition is essential for appropriate counselling and management planning.Keywords: ACD, Infantile pulmonary hypertension, Lung biopsy, Congenital lung disorder, FOXF1 Introduction Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD-MPV) is a rare developmental disorder of the pulmonary vasculature characterized by abnormal alveolar capillary formation and anomalous pulmonary venous positioning within the broncho-vascular bundle. These abnormalities result in impaired gas exchange and severe pulmonary hypertension due to markedly increased pulmonary vascular resistance [1,2]. Affected infants classically present during the neonatal period with severe hypoxemia and persistent pulmonary hypertension of the newborn (PPHN). Affected neonates typically deteriorate rapidly despite aggressive supportive therapy including mechanical ventilation, inhaled nitric oxide, and extracorporeal membrane oxygenation. The disease carries an extremely poor prognosis, and definitive diagnosis is usually established through lung biopsy or post-mortem examination [[2], [3], [4]]. Recent advances in molecular genetics have demonstrated that many cases of ACD-MPV are associated with mutations or deletions involving the FOXF1 gene, which plays an essential role in pulmonary vascular development. These genetic findings have contributed to a better understanding of the disease pathogenesis [5]. Although the classic presentation occurs shortly after birth, rare cases of delayed or atypical presentation beyond the neonatal period have been reported [[6], [7], [8]]. In such cases, patients may initially present with nonspecific respiratory symptoms or pulmonary hypertension without an obvious underlying cause, leading to diagnostic delay. We report a case of late-presenting ACD-MPV in an infant with severe pulmonary hypertension, highlighting the diagnostic challenges and emphasizing the importance of considering this rare condition when pulmonary hypertension remains unexplained. Case presentation A 7-month-old girl presented with progressive respiratory distress and hypoxemia requiring hospitalization. The patient was born at term following an uncomplicated pregnancy and delivery. APGAR scores were 7 and 9 at 1 and 5 minutes, respectively. She required brief supplemental oxygen for approximately 2 h after birth and was admitted for two days for management of neonatal jaundice. There was no history of persistent respiratory distress, persistent pulmonary hypertension of the newborn, prolonged oxygen requirement, or neonatal intensive care unit admission related to cardiorespiratory disease. According to the family and review of the medical records, she remained well throughout the neonatal period and early infancy. On exploring her history respiratory symptoms first became apparent at approximately 5–6 months of age, when she developed recurrent episodes of respiratory distress associated with poor weight gain, leading to multiple emergency department visits and outpatient evaluations. Initial clinical examination revealed tachypnea, oxygen requirement, and clinical findings suggestive of pulmonary hypertension. She was referred to the cardiology clinic where bedside echocardiography demonstrated moderate-to-severe pulmonary hypertension with dilated pulmonary arteries, a moderately dilated right ventricle, and moderate right atrial enlargement, with structurally normal cardiac anatomy and evidence of elevated pulmonary artery pressures. No congenital heart disease or intracardiac shunting sufficient to explain the severity of pulmonary hypertension was identified. Initial investigations did not support an infectious etiology. Chest radiography demonstrated bilateral infiltrates, more prominent in the right mid and lower lung zones (Fig. 1). She was admitted under cardiology care and treated with supplemental oxygen and diuretics (furosemide and spironolactone). Given the presence of severe pulmonary hypertension with right ventricular and right atrial enlargement on echocardiography, diuretic therapy was initiated to optimize preload and manage suspected right-sided volume overload. Chest computed tomography and ventilation–perfusion (V/Q) scanning revealed diffuse ground-glass opacities, an enlarged pulmonary trunk, and heterogeneous perfusion consistent with diffuse lung disease (Fig. 2). These findings raised concern for congenital lung disease, including surfactant dysfunction disorders, or atypical infection. Because of the severity and complexity of her presentation, cardiac catheterization was performed. Hemodynamic assessment confirmed severe pulmonary hypertension, with a mean pulmonary artery pressure of 50 mmHg and elevated pulmonary vascular resistance (PVRI 21 Wood units·m2), with no significant response to administration of 100% oxygen (PVRI decreased only to 18 Wood units·m2). No aortopulmonary shunt was identified. Sildenafil was initiated at a dose of 0.1 mg/kg/dose. Abdominal ultrasonography showed no evidence of portal hypertension. Chest radiography demonstrated bilateral infiltrates, more prominent in the right mid and lower lung zones. Widespread ground-glass opacities with enlarged pulmonary trunk. Several days later, the patient developed profuse diarrhea and abdominal distension. Abdominal radiography demonstrated dilated bowel loops with concern for pneumatosis intestinalis, and she developed hypovolemic shock. Necrotizing enterocolitis was suspected; however, imaging studies did not demonstrate definitive evidence of intestinal necrosis or portal venous gas. She was transferred to the pediatric cardiac intensive care unit for close monitoring and supportive management, including fluid resuscitation and broad-spectrum antibiotics. After clinical stabilization, flexible bronchoscopy and open lung biopsy were performed. Histopathologic examination was consistent with alveolar capillary dysplasia with misalignment of the pulmonary veins (Fig. 3). Genetic testing, including evaluation for FOXF1 abnormalities and other genes associated with pulmonary hypertension, was initiated during hospitalization. Results subsequently became available and did not identify any pathogenic or likely pathogenic variants. Parental testing likewise did not reveal pathogenic variants associated with pulmonary hypertension. On the following day, the patient developed worsening tachypnea and respiratory distress with progressive hypercapnia and respiratory acidosis despite non-invasive ventilation. She was intubated but shortly thereafter became bradycardic and suffered cardiac arrest. Advanced cardiopulmonary resuscitation was initiated; however, after 20 minutes, she was pronounced deceased. (A) Pulmonary artery muscularization, (B) Glomeruloid vessels: Represent abnormal capillary proliferation, seen in ACD, mimicking renal glomeruli. (C) Thick Alveolar Septa. (D) Vein misalignment, vein run alongside pulmonary arteriole, both encased by same adventitia. Timeline of clinical course and diagnostic evaluation Discussion ACD-MPV is a rare and fatal developmental lung disorder characterized by abnormal formation of the alveolar–capillary interface and pulmonary vascular bed, resulting in severe pulmonary hypertension that is typically resistant to standard therapies. This case adds to the limited literature describing late clinical presentation of ACD-MPV beyond the neonatal period. Although the diagnosis was established several weeks after symptom onset, the patient remained asymptomatic throughout the neonatal period and early infancy, with clinical manifestations first appearing at approximately 5–6 months of age. This presentation contrasts with the classic neonatal phenotype and further expands the recognized clinical spectrum of ACD-MPV. Importantly, the absence of neonatal respiratory distress, persistent pulmonary hypertension of the newborn, or prolonged oxygen requirement further supports the atypical timing of disease manifestation in this patient. ACD-MPV is associated with pathogenic variants or deletions involving the FOXF1 gene or its regulatory region on chromosome 16q24.1 [1]. Recent studies suggest that targeted genetic testing can identify FOXF1-related abnormalities in a substantial proportion of suspected cases, supporting its role in diagnosis and genetic counselling [2]. Although FOXF1 abnormalities have been identified in a substantial proportion of patients with ACD-MPV, not all cases demonstrate an identifiable molecular defect. In our patient, comprehensive genetic testing, including FOXF1 analysis and evaluation for other pulmonary hypertension-related genes, did not identify a pathogenic variant. This finding highlights the genetic heterogeneity of ACD-MPV and emphasizes that a negative genetic evaluation does not exclude the diagnosis when characteristic histopathological features are present. In such circumstances, lung biopsy remains the diagnostic gold standard. Histologically, ACD-MPV is characterized by thickened alveolar septa, reduced capillary density, and misaligned pulmonary veins coursing alongside pulmonary arteries, impairing gas exchange and contributing to fixed pulmonary vascular disease [3,4]. The relatively prolonged survival observed in our patient compared with the classic neonatal presentation may reflect the recognized phenotypic heterogeneity of ACD-MPV. Previous reports have suggested that patients with patchy pulmonary involvement or less extensive vascular abnormalities may present later in infancy and survive longer than those with diffuse disease. Such variability may contribute to delayed recognition and supports the concept that ACD-MPV exists along a broader clinical spectrum than initially appreciated. The gastrointestinal deterioration observed during hospitalization deserves consideration. Although necrotizing enterocolitis was initially suspected, imaging studies did not demonstrate definitive evidence of intestinal necrosis or portal venous gas. The abdominal distension, diarrhea, and subsequent hemodynamic instability may have reflected systemic hypoperfusion in the setting of severe pulmonary hypertension and evolving right ventricular dysfunction. Alternatively, gastrointestinal manifestations have occasionally been described in association with FOXF1-related developmental disorders and ACD-MPV. Given the absence of definitive radiologic findings and the rapid clinical deterioration, the precise mechanism in our patient remains uncertain [3,4]. Cardiac catheterization demonstrated markedly elevated pulmonary artery pressure and pulmonary vascular resistance. Notably, the absence of a meaningful response to 100% oxygen supported a fixed pulmonary vascular pathology rather than reversible hypoxic vasoconstriction. This case underscores that absent pulmonary vasoreactivity in infancy should prompt early consideration of structural pulmonary vascular disorders rather than escalation of vasodilator therapy alone. This hemodynamic profile is characteristic of ACD-MPV and provides an important clinical clue distinguishing it from other causes of pulmonary hypertension in infancy. Pulmonary vasodilators such as sildenafil and inhaled nitric oxide are frequently used in PH management; however, their benefit in ACD-MPV is often limited due to the underlying structural abnormalities of the pulmonary vasculature [3]. Supportive therapies, including mechanical ventilation and extracorporeal membrane oxygenation (ECMO), may provide temporary stabilization but do not reverse disease progression. Lung transplantation remains the only potentially life-prolonging therapy; however, in our case, rapid respiratory deterioration and hemodynamic instability precluded timely consideration for transplant. Bronchoscopy may assist in excluding infection or alternative diagnoses such as pulmonary alveolar proteinosis, particularly when immunodeficiency is considered. Nevertheless, lung biopsy remains the definitive diagnostic modality in suspected ACD-MPV. While most reported cases present within days of birth, delayed presentations with milder early courses have been described [[6], [7], [8]]. Our patient shares similarities with previously reported late-presenting cases but differed by exhibiting a gradual, insidious decline rather than abrupt decompensation and by lacking extrapulmonary manifestations. Delayed presentations of ACD-MPV remain rare but increasingly recognized, highlighting the importance of early consideration in atypical cases. Conclusion Although genetic testing is increasingly used as a non-invasive diagnostic tool in suspected ACD-MPV, results may be unavailable, declined, or insufficient to guide urgent clinical decisions. In such settings, lung biopsy remains critical for timely diagnosis. Given the poor prognosis without lung transplantation, early recognition of ACD-MPV in infants with refractory pulmonary hypertension and diffuse lung disease is essential to facilitate appropriate counselling, consideration of transplant referral, and avoidance of prolonged ineffective therapies. Heightened clinical awareness may help shorten diagnostic delay and improve decision-making for affected families. Data availability statement The data supporting the findings of this study are included within the article. Additional data may be available from the corresponding author upon reasonable request. Ethical approval Ethical approval was obtained from the Institutional Review Board of King Abdullah International Medical Research Centre. Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. CRediT authorship contribution statement Tamer Abusido: Conceptualization, Formal analysis, Investigation, Supervision, Visualization, Writing – review & editing. Saleh Alshaibi: Formal analysis, Project administration, Writing – original draft. Abdullah Aldraihem: Data curation, Formal analysis, Writing – original draft. Abdulmajeed Alfadhel: Project administration, Validation, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. References Associated Data Data Availability Statement The data supporting the findings of this study are included within the article. Additional data may be available from the corresponding author upon reasonable request.